ReviewPharmaceuticals (Basel, Switzerland)2026

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective.

Nicolò Bisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.